Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 1
2007 1
2009 5
2010 2
2011 1
2012 3
2013 2
2014 2
2015 1
2016 3
2017 4
2018 3
2019 2
2020 1
2021 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072.
Stroh M, Green M, Millard BL, Apgar JF, Burke JM, Garner W, Lu H, Lyman SK, Desnoyers LR, Richardson J, Hannah A, Kavanaugh WM. Stroh M, et al. Clin Pharmacol Ther. 2021 Feb;109(2):383-393. doi: 10.1002/cpt.1985. Epub 2020 Aug 31. Clin Pharmacol Ther. 2021. PMID: 32681519
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.
Johnson M, El-Khoueiry A, Hafez N, Lakhani N, Mamdani H, Rodon J, Sanborn RE, Garcia-Corbacho J, Boni V, Stroh M, Hannah AL, Wang S, Castro H, Spira A. Johnson M, et al. Among authors: stroh m. Clin Cancer Res. 2021 Aug 15;27(16):4521-4530. doi: 10.1158/1078-0432.CCR-21-0194. Epub 2021 Jun 3. Clin Cancer Res. 2021. PMID: 34083236 Clinical Trial.
The minimal impact of food on the pharmacokinetics of ridaforolimus.
Stroh M, Li X, Marsilio S, Panebianco D, Johnson-Levonas A, Juan A, Orford K, Agrawal N, Trucksis M, Wagner JA, Murphy G, Iwamoto M. Stroh M, et al. Cancer Chemother Pharmacol. 2012 Jul;70(1):177-82. doi: 10.1007/s00280-012-1897-8. Epub 2012 Jun 6. Cancer Chemother Pharmacol. 2012. PMID: 22669570 Clinical Trial.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil-Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A. Naing A, et al. Among authors: stroh m. J Immunother Cancer. 2021 Jul;9(7):e002447. doi: 10.1136/jitc-2021-002447. J Immunother Cancer. 2021. PMID: 34301809 Free PMC article.
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Sanborn RE, Hamid O, de Vries EG, Ott PA, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Cho DC, Plummer R, Stroh M, Lu L, Thistlethwaite F. Sanborn RE, et al. Among authors: stroh m. J Immunother Cancer. 2021 Jul;9(7):e002446. doi: 10.1136/jitc-2021-002446. J Immunother Cancer. 2021. PMID: 34301808 Free PMC article. Clinical Trial.
34 results